New York Stock Exchange · Healthcare
Invest in Novo Nordisk stock from India
Indian and foreign residents can buy Novo Nordisk (NVO) shares directly through Paasa.
By Paasa · Updated
Novo Nordisk at a glance
- Price
- $38.52-$0.11 (0.27%)
- Market cap
- $171.03B
- Day range
- $38.41 – $38.83
- P/E
- 9.65
- Dividend yield
- 4.62%
- Volume
- 5.69M
- 1 month
- -20.85%
- 6 months
- +6.01%
- YTD
- -24.30%
- 1 year
- -31.27%
- 5 years
- -22.25%
Novo Nordisk statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | DKK 309.1B | DKK 290.4B | DKK 232.3B | DKK 177.0B | DKK 140.8B |
| Gross profit | DKK 250.3B | DKK 245.9B | DKK 196.5B | DKK 148.5B | DKK 117.1B |
| Operating income | DKK 127.7B | DKK 128.3B | DKK 102.6B | DKK 74.8B | DKK 58.6B |
| Net income | DKK 102.4B | DKK 101.0B | DKK 83.7B | DKK 55.5B | DKK 47.8B |
| Earnings per share | DKK 23.06 | DKK 22.67 | DKK 18.67 | DKK 12.26 | DKK 10.40 |
| EBITDA | DKK 156.7B | DKK 147.9B | DKK 114.6B | DKK 76.8B | DKK 65.4B |
| Total assets | DKK 542.9B | DKK 465.8B | DKK 314.5B | DKK 241.3B | DKK 194.5B |
| Total debt | DKK 131.0B | DKK 102.8B | DKK 27.0B | DKK 25.8B | DKK 26.6B |
| Cash and short-term investments | DKK 27.0B | DKK 26.3B | DKK 30.2B | DKK 23.6B | DKK 17.5B |
| Shareholders' equity | DKK 194.0B | DKK 143.5B | DKK 106.6B | DKK 83.5B | DKK 70.7B |
| Operating cash flow | DKK 119.1B | DKK 121.0B | DKK 108.9B | DKK 78.9B | DKK 55.0B |
| Free cash flow | DKK 29.0B | DKK 69.7B | DKK 70.0B | DKK 64.1B | DKK 47.6B |
| Capital expenditure | −DKK 90.1B | −DKK 51.3B | −DKK 38.9B | −DKK 14.8B | −DKK 7.4B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in DKK; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Merck | MRK | $147.79 | $365.01B |
| Novartis | NVS | $144.95 | $275.50B |
| AstraZeneca | AZN | $166.27 | $257.73B |
| Thermo Fisher Scientific | TMO | $669.14 | $247.41B |
| Amgen | AMGN | $410.47 | $221.53B |
| Gilead Sciences | GILD | $148.81 | $184.52B |
| Abbott Laboratories | ABT | $101.09 | $174.92B |
| Pfizer | PFE | $28.35 | $161.55B |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- $40.00
- High
- $47.00
- Median
- $47.00
- Consensus
- $44.67
Ratings: 23 buy · 13 hold · 3 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Novo Nordisk from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search NVO and buy
Find Novo Nordisk by name or by its ticker, NVO, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in Novo Nordisk from India
What Novo Nordisk does
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. Novo Nordisk operates in the Drug Manufacturers - General industry within the Healthcare sector.
Hold a dollar asset
Novo Nordisk shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one Novo Nordisk share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Novo Nordisk stock from India?
Yes. Indian residents and NRIs can buy Novo Nordisk (NVO) shares directly through Paasa. Novo Nordisk is listed on the New York Stock Exchange, in the Drug Manufacturers - General industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Novo Nordisk share?
No. You can buy part of one Novo Nordisk share and add to your position over time. One share is $38.52, and you can buy whole shares or any fraction; there is no minimum trade size.
How are Novo Nordisk dividends taxed for Indian investors?
Novo Nordisk trades on the New York Stock Exchange but is domiciled in Denmark, so any withholding on its dividends follows that country's rules rather than those of the US. What trades there is a depositary receipt over Novo Nordisk shares rather than the ordinary share itself. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Novo Nordisk shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.